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To capture both MDS and myeloproliferative neoplasm (MPN) features in a singly response scale in CMML, an international expert panel, the MDS/MPN International Working Group, proposed new response criteria for MDS/MPN, hereafter referred to as overlap-MDS/MPN criteria. 11 These new criteria take in consideration bone marrow and peripheral blood blast reduction and improvement of cytopenias, but also account for correction of WBC, monocyte and peripheral immature myeloid cell counts (IMC), regression of splenomegaly and other extra-medullary disease. These criteria also assess correction of myelofibrosis, generally moderate in CMML, 12 and propose a provisional entity of 'clinical benefit' solely based on improvement assessed with the MPN-SAF scoring system, 13 which has been developed in primary myelofibrosis and has never been validated in MDS/MPN. These new criteria remain to be validated.
To No patient achieved PR; 19% patients had SD without HI and 24% had progressive disease (PD). Regarding overlap-MDS/MPN criteria, the ORR was 71%. In our dataset, improvement of clinical symptoms was assessed retrospectively by reviewing patients' charts, instead of applying the MPN-SAF scoring system 13 as recommended. Similarly, we could not evaluate improvement of myelofibrosis, because the use of trephine biopsies is not part of the French guidelines for CMML. However, diffuse myelofibrosis is infrequent in CMML and can be suspected in case of dry tap. Overlap-MDS/MPN responses included CR in 13%, optimal marrow response (OMR) with clinical benefit (CB) in 18% (including CB in spleen size (CB-Spl) 6%, and CB in general symptoms (CB-Sym) 1%), OMR without CB in 15%, partial marrow response (PMR) in 1% and SD with CB in 24% (including CB-Spl 5%, and CB-Sym 1%). No patient achieved PR. Twenty-four percent of patients had SD, and 5% had progressive disease.
Overall response status at best response between IWG-2006 and overlap-MDS/MPN was concordant in 86% of cases, corresponding to a Cohen's Kappa 15 of.7, indicating a relatively good agreement between response criteria. Sources of discrepancies are summarized in Table 1 Eleven patients received ASCT, after a median of 6 cycles (IQR 3-13) of HMA, including 9 who had reached a response per overlap-MDS/MPN criteria (three OMR with CB, four OMR, two CB, including one CB-Spl), and only 4 of whom had reached a response per IWG-2006 criteria (3 HI and 1 mCR). One patient had spleen size reduction and was classified as stable disease per IWG-2006 criteria, and the remaining four patients were classified as progressive disease because of worsening cytopenias The small number of transplanted patients precludes analysis of post-transplant outcome, but these data suggest overlap-MDS/MPN responses encompass clinically meaningful improvement already considered for the decision to transplant in daily practice.
Finally, the impact on OS of dissociated responses was difficult to assess because of the small number of patients (n = 11), achieving a response per overlap-MDS/MPN but not per IWG-2006 criteria, and because five of them subsequently received allogeneic transplantation.
In conclusion, we report the first retrospective validation of these new overlap-MDS/MPN criteria in the setting of CMML treated with HMA. By taking into account improvement of myeloproliferative features and by allowing to classify patients with dissociated responses more easily, not considering isolated increase in bone marrow blasts or worsening of cytopenia as a progression, overlap-MDS/MPN criteria increase response rates as well as response duration.
These criteria remain to be evaluated in prospective studies, with a comprehensive evaluation of clinical symptoms and systematic cytogenetic examinations, to confirm their contribution in defining robust short-term endpoints for future CMML clinical trials.
